Regression of liver fibrosis in cases of chronic liver disease type C: quantitative evaluation by using computed image analysis.

OBJECT It was reported that the liver fibrosis is reduced in patients with chronic liver disease type C after eradication of HCV. Degree of fibrosis was expressed by the classical fibrosis scoring system (F0-F4) at present. However a change of subtle reduction of fibrosis cannot be expressed in its fibrosis score and thus we measured an area of fibrosis and compared detailed change of the fibrosis area in paired liver biopsy. METHODS For quantitative assessment of liver fibrosis, we measured an area of fibrosis using computed digital image analysis and pursued the rate of a fibrosis area for whole biopsied liver tissue of 25 patients with HCV infection (20 complete response patients to IFN therapy who showed viral eradication: CR and 5 non-treated ones with IFN but had conservative therapy: CT). RESULTS In CR group, fibrosis rate was 7.2 +/- 1.5% before therapy, 2.7 +/- 0.5% after the therapy and they were significantly regressed. In CT group, fibrosis rate was 8.4 +/- 4.3% at the first biopsy, 15.9 +/- 7.7% at the second biopsy. CONCLUSIONS Regression of liver fibrosis could be confirmed in patients with virologic response to IFN even in patients with liver cirrhosis. Our quantitative evaluation provided information superior to that obtained by the classical fibrosis staging score system.

[1]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[2]  J. Hoofnagle,et al.  10‐year follow‐up after interferon‐α therapy for chronic hepatitis C , 1998 .

[3]  J. Ludwig,et al.  The nomenclature of chronic active hepatitis: an obituary. , 1993, Gastroenterology.

[4]  K. Chayama,et al.  Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection. , 1997, Journal of hepatology.

[5]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[6]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[7]  L. Benvegnu' Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. , 1998, Lancet.

[8]  J. Izopet,et al.  Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. , 2001, Journal of hepatology.

[9]  N. Hayashi,et al.  Long-term biochemical and virological response to natural interferon-α in patients with chronic hepatitis C , 1996, Digestive Diseases and Sciences.

[10]  M. Shindo,et al.  Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. , 1995, Annals of internal medicine.

[11]  M. Shindo,et al.  The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. , 1997, Journal of hepatology.

[12]  M. Shindo,et al.  Hepatic Hepatitis C Virus RNA as a Predictor of a Long-Term Response to Interferon- Therapy , 1995, Annals of Internal Medicine.

[13]  P. Marcellin,et al.  Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon- Therapy , 1997, Annals of Internal Medicine.

[14]  H. Asakura,et al.  Interferon Inhibits Progression of Liver Fibrosis and Reduces the Risk of Hepatocarcinogenesis in Patients with Chronic Hepatitis C: A Retrospective Multicenter Analysis of 652 Patients , 2004, Digestive Diseases and Sciences.

[15]  M. Kaplan,et al.  Regression of Hepatic Fibrosis in Hepatitis C with Long-Term Interferon Treatment , 1998, Digestive Diseases and Sciences.

[16]  J. Koskinas,et al.  Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa‐2b for 6 or 12 months: A 4‐year follow‐up of 211 patients , 1997, Hepatology.

[17]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[18]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[19]  Valeer J Desmet,et al.  Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. , 2003, Journal of hepatology.

[20]  N. Hayashi,et al.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C , 1998, Hepatology.

[21]  Y. Imai,et al.  Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 1998, Annals of Internal Medicine.

[22]  N. Hayashi,et al.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. , 1995, Journal of hepatology.

[23]  J. Hoofnagle,et al.  10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. , 1998, Hepatology.